View in EDS

Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.

Saved in:
Bibliographic Details
Title: Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.
Authors: Miauton A; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland. Electronic address: alix.miauton@unisante.ch., Audran R; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland., Besson J; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Maby-El Hajjami H; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland., Karlen M; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Warpelin-Decrausaz L; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland; Research Support Unit, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Sene L; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland., Schaufelberger S; Information Systems and Digital Transformation, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Faivre V; Information Systems and Digital Transformation, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Faouzi M; Biostatistics Unit, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Hartley MA; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland., Spertini F; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland., Genton B; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.
Source: EBioMedicine [EBioMedicine] 2024 Jan; Vol. 99, pp. 104922. Date of Electronic Publication: 2023 Dec 20.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article
Journal Info: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38128414
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Miauton+A%22">Miauton A</searchLink>; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland. Electronic address: alix.miauton@unisante.ch.<br /><searchLink fieldCode="AU" term="%22Audran+R%22">Audran R</searchLink>; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Besson+J%22">Besson J</searchLink>; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Maby-El+Hajjami+H%22">Maby-El Hajjami H</searchLink>; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Karlen+M%22">Karlen M</searchLink>; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Warpelin-Decrausaz+L%22">Warpelin-Decrausaz L</searchLink>; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland; Research Support Unit, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Sene+L%22">Sene L</searchLink>; Clinical Trial Unit, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne, Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Schaufelberger+S%22">Schaufelberger S</searchLink>; Information Systems and Digital Transformation, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Faivre+V%22">Faivre V</searchLink>; Information Systems and Digital Transformation, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Faouzi+M%22">Faouzi M</searchLink>; Biostatistics Unit, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Hartley+MA%22">Hartley MA</searchLink>; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Spertini+F%22">Spertini F</searchLink>; Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.<br /><searchLink fieldCode="AU" term="%22Genton+B%22">Genton B</searchLink>; Tropical, Travel and Vaccination Clinic, Centre for Primary Care and Public Health (Unisanté), Lausanne, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101647039%22">EBioMedicine</searchLink> [EBioMedicine] 2024 Jan; Vol. 99, pp. 104922. <i>Date of Electronic Publication: </i>2023 Dec 20.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Clinical Trial, Phase I; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+B%2EV%22">Elsevier B.V </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>101647039 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3964 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523964%22">23523964 </searchLink><i>NLM ISO Abbreviation: </i>EBioMedicine <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38128414
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ebiom.2023.104922
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 104922
    Titles:
      – TitleFull: Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Miauton A
      – PersonEntity:
          Name:
            NameFull: Audran R
      – PersonEntity:
          Name:
            NameFull: Besson J
      – PersonEntity:
          Name:
            NameFull: Maby-El Hajjami H
      – PersonEntity:
          Name:
            NameFull: Karlen M
      – PersonEntity:
          Name:
            NameFull: Warpelin-Decrausaz L
      – PersonEntity:
          Name:
            NameFull: Sene L
      – PersonEntity:
          Name:
            NameFull: Schaufelberger S
      – PersonEntity:
          Name:
            NameFull: Faivre V
      – PersonEntity:
          Name:
            NameFull: Faouzi M
      – PersonEntity:
          Name:
            NameFull: Hartley MA
      – PersonEntity:
          Name:
            NameFull: Spertini F
      – PersonEntity:
          Name:
            NameFull: Genton B
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2024 Jan
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2352-3964
          Numbering:
            – Type: volume
              Value: 99
          Titles:
            – TitleFull: EBioMedicine
              Type: main
ResultId 1